Department of Vascular Surgery, General Hospital of Ningxia Medical University, Yinchuan, China.
Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2630-2639. doi: 10.26355/eurrev_201903_17413.
Critical lower-limb ischemia (CLLI) is characterized by high morbidity and mortality. The aim of this study was to explore the effectiveness of the combination of cell therapy with apelin-13 and hyperbaric oxygen in CLLI animal model.
The experimental ischemic rats were divided into five groups, including negative control, bone marrow derived mononuclear cells (BM-MNCs), apelin-13, hyperbaric oxygen treatment (HBOT) and apelin-13 with HBOT group. Each group was composed of 10 rats. Endothelial progenitor cells (EPCs) derived from bone marrow were transplanted into the ischemia rat model. After 3 weeks of transplantation, the formation of new vessels was evaluated by examining cluster of differentiation (CD)31, CD34 and vascular endothelial growth factor receptor 2 (VEGFR-2) expressions as well as a direct vision of vessels by hematoxylin and eosin (HE) staining and immunohistochemistry.
Compared with the negative control group, both angiogenic factors expressions and the number of new vessels increased notably by the transplantation of BM-MNCs in the ischemic models. Apelin-13 or HBOT alone improved the efficacy within limit while the combination of the three elements remarkably promoted the neovascularization in ischemic limbs.
BM-MNC induced angiogenesis in the ischemic limbs and was considered an effective resource for cell therapy. The preliminary data of this study showed that the combination of cell therapy with apelin-13 and HBOT improved the efficacy of angiogenesis.
严重下肢缺血（CLI）具有高发病率和死亡率的特点。本研究旨在探讨细胞疗法联合apelin-13 和高压氧（HBOT）在 CLI 动物模型中的有效性。
实验性缺血大鼠分为五组，包括阴性对照组、骨髓来源的单核细胞（BM-MNC）组、apelin-13 组、HBOT 组和 apelin-13 联合 HBOT 组，每组 10 只大鼠。将骨髓来源的内皮祖细胞（EPCs）移植到缺血大鼠模型中。移植 3 周后，通过 CD31、CD34 和血管内皮生长因子受体 2（VEGFR-2）的表达以及苏木精和伊红（HE）染色和免疫组织化学直接观察血管来评估新血管的形成。
与阴性对照组相比，BM-MNC 移植可明显增加缺血模型中血管生成因子的表达和新血管的数量。apelin-13 或 HBOT 单独使用在一定程度上提高了疗效，而三种方法联合使用则显著促进了缺血肢体的新生血管形成。
BM-MNC 可诱导缺血肢体血管生成，被认为是细胞治疗的有效资源。本研究的初步数据表明，细胞疗法联合 apelin-13 和 HBOT 可提高血管生成的疗效。
